Use of agonists and antagonists of IL-23 in the treatment of viral infection
View Patent ↗Provided are methods of modulating cytokine activity, e.g., for the purpose of treating viral infections. Also provided are reagents for use in screening for agonists or antagonists of IL-23.
1. A method of modulating CD8 + T cell response to a viral infection comprising administering an effective amount of an antagonist of IL-23, wherein:
i) the antagonist of IL-23 specifically binds to p19 or IL-23R;
ii) the viral infection is caused by:
a) a respiratory virus;
b) a mucosal virus; or
c) an influenza virus;
and
iii) said modulating CD8 + T cell response comprises increasing the ex vivo cytotoxicity of CD8 + T cells,
wherein the antagonist comprises an antibody or a fragment thereof that specifically binds to p19 or IL-23R.
2. The method of claim 1 , wherein the antagonist comprises an antibody or a fragment thereof that specifically binds to p19.
3. The method of claim 2 , wherein the antibody or a fragment thereof comprises a monoclonal antibody or fragment thereof.
4. The method of claim 1 , wherein the viral infection is caused by a mucosal virus.
5. The method of claim 1 , wherein the viral infection is caused by:
a) influenza A;
b) influenza B; or
c) influenza C.
6. The method of claim 1 , wherein the viral infection comprises:
a) a respiratory syndrome; or
b) pneumonia.
7. The method of claim 1 , wherein the antibody or fragment thereof specifically binds to IL-23R.
8. The method of claim 2 , wherein the antibody or fragment thereof comprises a humanized antibody or antigen-binding fragment thereof.
9. The method of claim 2 , wherein the antibody fragment is an Fab, Fv, or F(ab′)2 fragment.
10. The method of claim 7 , wherein the antibody or fragment thereof comprises a monoclonal antibody or fragment thereof.
11. The method of claim 7 , wherein the antibody or fragment thereof comprises a humanized antibody or antigen-binding fragment thereof.
12. The method of claim 7 , wherein the antibody fragment is an Fab, Fv, or F(ab′)2 fragment.
13. The method of claim 1 , wherein the ex vivo cytotoxicity of CD8 + T cells is measured by chromium release.